The purpose of this mono therapy study is to evaluate the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of BCD-145 (JSC BIOCAD, Russia) in patients with unresectable/metastatic melanoma
Latest Information Update: 01 Jul 2024
At a glance
- Drugs Nurulimab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Biocad
Most Recent Events
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 15 Apr 2019 Status changed from recruiting to completed.
- 23 Mar 2018 New trial record